A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3947-3952

  Yamauchi, Takahiro ^a   Negoro, Eiju ^a   Lee, Shin ^a   Takai, Mihoko ^a   Matsuda, Yasufumi ^a   Takagi, Kazutaka ^a   Kishi, Shinji ^a   Tai, Katsunori ^a   Hosono, Naoko ^a   Tasaki, Toshiki ^a   Ikegaya, Satoshi ^a   Inai, Kunihiro ^a   Yoshida, Akira ^a   Urasaki, Yoshimasa ^a   Iwasaki, Hiromichi ^a   Ueda, Takanori ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

AML; Prognosis; Uric acid

Indexed keywords

BARASERTIB; CYTARABINE; IDARUBICIN; LACTATE DEHYDROGENASE; URIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HOSPITAL ADMISSION; HUMAN; INDUCTION CHEMOTHERAPY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; URIC ACID BLOOD LEVEL;

AML; PROGNOSIS; URIC ACID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; URIC ACID;

EID: 84884991835     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Coiffier B, Altman A, Pui CH, Younes A and Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 26: 2767-2778, 2008.
2. Cairo MS, Coiffier B, Reiter A and Younes A; TLS Expert Panel: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: An expert TLS panel consensus. Br J Haematol 149: 578-586, 2010.
3. Howard SC, Jones DP and Pui C-H: The tumor lysis syndrome. N Engl J Med 364: 1844-1854, 2011.
4. Dhankhar R, Dahiya K, Sharma TK, Ghalaut VS, Atri R and Kaushal V: Diagnostic significance of adenosine deaminase, uric acid and C-reactive protein levels in patients of head and neck carcinoma. Clin Lab 57: 795-798, 2011.
5. Burnett A, Wetzler M and Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29: 487-494, 2011.
6. Roboz GJ: Current treatment of acute myeloid leukemia. Curr Opin Oncol 24: 711-719, 2012.
7. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, RAcil Z, Rowe JM, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D and Ossenkoppele GJ: The European Leukemia Net AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach. Nat Rev Clin Oncol 9: 579-590, 2012.
8. Estey EH: Acute myeloid leukemia: 2013 update on riskstratification and management. Am J Hematol 88: 318-327, 2013.
9. Kühnl A and Grimwade D: Molecular markers in acute myeloid leukaemia. Int J Hematol 96: 153-163, 2012.
10. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ and Burnett AK, National Cancer Research Institute Adult Leukaemia Working Group: Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116: 354-365, 2010.
11. Patel JP and Levine RL: How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012: 28-34, 2012.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620-625, 1985.
13. Tsuboi K, Yokozawa T, Sakura T, Watanabe T, Fujisawa S, Yamauchi T, Uike N, Ando K, Kihara R, Tobinai K, Asou H, Hotta T and Miyawaki S: A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia. Leuk Res 35: 1384-1389, 2011.
14. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R and Bloomfield CD: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649, 2003.
15. Krakoff IH and Meyer RL: Prevention of hyperuricemia in leukemia and lymphoma: Use of alopurinol, a xanthine oxidase inhibitor. JAMA 193: 1-6, 1965.
16. Seegmiller JE, Laster L and Howell RR: Biochemistry of uric acid and its relation to gout. N Engl J Med 268: 712-716, 1963.
17. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ and Estey EH: The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: Analysis of 1,180 patients. Clin Cancer Res 14: 721-730, 2008.
18. Inai K, Tsutani H and Ueda T: Hyperuricemia associated with hematological malignancies. Gout Nucl Acid Metab 23: 181-186, 1999.